Concord Biotech Secures USFDA Approval for Tofacitinib Tablets, Targets USD 500 Million US Market
We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok